Advocate Aurora Health (AAH) is a non-profit health care system with dual headquarters located in Milwaukee, Wisconsin, and Downers Grove, Illinois. As of 2021, the AAH system has 26 hospitals and more than 500 sites of care, with 75,000 employees, including 10,000 employed physicians. The health system formed as a result of a merger between Illinois-based Advocate Health Care and Wisconsin-based Aurora Health Care. AAH is a teaching affiliate of the University of Wisconsin School of Medicine and Public Health.
BACKGROUND:The objective of this cluster randomized controlled trial was to determine the feasibility and safety of an intensive (systolic blood pressure [SBP] <120 mm Hg) versus usual care (SBP <140 mm Hg) approach to SBP control in patients with renal cell or thyroid cancer initiating VEGFR (vascular endothelial growth factor)-tyrosine kinase inhibitors. METHODS:A phase II site-based cluster randomized controlled trial compared intensive SBP control to usual care, incorporating a centralized BP advisory core to guide BP management. Patients underwent home BP monitoring and study visits at baseline, 1, 2, 3, and 6 months. SBP was compared between the 2 study arms using bootstrapped CIs. Common Terminology Criteria for Adverse Events and patient-reported outcomes were summarized. RESULTS:Overall, 61 patients with renal cell (n=58) or thyroid cancer (n=3) from 10 sites were enrolled; 30 at 5 sites were randomized to intensive SBP control and 31 at 5 sites to usual care. A lower SBP was observed in the intensive SBP control arm compared with usual care, with mean differences of -12.2 (95% CI, -18.1 to -7.0) mm Hg at 1 month, -7.6 (95% CI, -15.3 to -0.4) mm Hg at 3 months, and -6.9 (95% CI, -19.3 to 6.0) mm Hg at 6 months. In the usual care arm, Grade 3 Common Terminology Criteria for Adverse Events for kidney injury (n=4), hypotension (n=3), and dyspnea (n=2) were numerically greater compared with the intensive SBP control (n=1, 2, and 0, respectively). Patient-reported outcomes were largely similar between the 2 groups. CONCLUSIONS:This first-ever randomized controlled trial of SBP control in an active cancer population demonstrates the feasibility, safety, and tolerability of intensive SBP control with VEGFR tyrosine kinase inhibitors. REGISTRATION:URL: https://www.clinicaltrials.gov; Unique identifier: NCT04467021.
Introduction: Withdrawal of cardiac vagal tone and sympathetic stimulation are the dominant mechanisms for heart rate (HR) increase during exercise. We present a case with paradoxical vagal response during exercise, resulting in sinus pause and syncope with ischemic changes. Patient Information: A 53-year-old female with past medical history of bilateral breast cancer post-radiation therapy, radiation-induced valvular heart disease, and grade 2 diastolic heart failure (HF), was complaining of recurrent syncope with exercise. Clinical Findings & Timeline: EKG showed sinus rhythm with right bundle branch block. On treadmill exercise test, HR increased from baseline 88 bpm to 121 bpm during stage 1 and plateaued at 122 bpm at stage 2. At stage 3, the HR dropped to below 30 bpm with unmeasurable BP, associated with syncope. EKG showed sinus bradycardia followed by sinus pauses up to 5 seconds. Ischemic changes on EKG also noted (Figure). HR recovered after 4 minutes with resolution of the ischemic changes and improvement in symptoms. Diagnostic Assessment & Reasoning: A coronary angiogram showed mild CAD. Therapeutic Intervention(s): Later, the patient underwent a dual-chamber pacemaker implant. Discussion & Synthesis: We present a case of syncope resulting from hypervagal response during exercise. We hypothesize that, in a patient with known diastolic HF, an increase in cardiac contractility and in LV end-diastolic pressure during exercise resulted in activation of the LV mechanoreceptors (C-fibers) and an increase in parasympathetic tone through vagal activation. This vagal activation led to sinus node suppression and vasodilation. We also hypothesize that the hypervagal response resulted in elevation of intra-coronary acetylcholine, which led to coronary artery spasms and the ischemic changes noted on stress test.
Background: Previous retrospective research displayed similar safety and efficacy between 1 and 2 Perclose devices (Abbott, Abbott Park, Ill.) used for transcatheter aortic valve replacement (TAVR), potentially reducing associated complications and healthcare costs. We identified a lack of randomized controlled trials (RCTs). Aim: To investigate the differences in postoperative health outcomes between 1 and 2 Perclose devices in an RCT. Methods: Our ongoing single-center, prospective, single vs. dual large-bore access closure TAVR (SOLO-TAVR) RCT is currently enrolling adult patients with severe aortic stenosis undergoing transfemoral TAVR with the CoreValve (Medtronic, Minneapolis, Minn.) using 14-French sheaths (ClinicalTrial.gov ID: NCT06871774). Participants are randomly assigned to 1 or 2 Perclose devices for pre-closing TAVR. Primary outcomes are life-threatening bleeding, major or minor bleeding without threat to life (within 24 hours post-procedure), major or minor vascular complications (within index hospitalization), and time to hemostasis (post-procedure). Secondary outcomes include the use of additional closure devices (within 24 hours post-procedure), in-hospital serious vascular complications requiring percutaneous or surgical interventions, and limb ischemia related to TAVR (30-days post-procedure). Outcomes were recorded intra-operatively, during index hospitalization, and 30 days postoperatively. Outcomes were defined according to the 2021 Valve Academic Research Consortium (VARC-3) criteria. The composite endpoint was composed of all the categorical complications. We used Fisher’s exact test and Wilcoxon rank-sum test with an intent-to-treat analysis approach. Results: A total of 81 patients were enrolled successfully based on eligibility criteria from August 14, 2025, through March 16, 2026. Sample characteristics and results are shown in Table 1 and Figure 1. There was no significant difference between 1 and 2 Perclose device use when comparing the composite endpoint (p=1.00), time to hemostasis (p=0.24), and time to compression (p=0.14). Conclusion: Thus far, our study demonstrates that one Perclose device may be as safe as 2 Perclose devices for TAVR.
Background: Hospital procedure volumes have been shown to impact clinical outcomes following transcatheter aortic valve replacement (TAVR). There is limited data regarding emergent TAVR. Research Questions/Hypothesis: Among adult patients undergoing emergent TAVR, do hospital procedural volumes (low vs. medium vs. high) influence in-hospital outcomes — specifically mortality, length of stay, and total hospital charges? Methods: We identified adult patients undergoing emergent TAVR utilizing the National Inpatient Sample from 2016-2022. Hospitals were categorized into tertiles of annual TAVR volume (low, medium, high). Survey-weighted analyses were performed to assess mortality, LOS, and total hospital charges (inflation-adjusted to 2022 USD) across tertiles. Results: A total of 71,728 patients undergoing emergent TAVR were included. Across the study period, the overall in-hospital mortality was 2.7% (95% CI: 2.5-3%). Mortality was highest in low-volume centers (3.1%), followed by medium centers (2.8%), and high centers (2.2%) (p<0.001 in all). Mean LOS decreased with increasing volume (low: 10 days, medium: 9.1 days, high: 7.1 days) (Figure 1A). Mean total hospital charge varied by tertile (low: $71,664, medium: $67,506, high: $60,675) (Figure 1B). Conclusion: Patients undergoing emergent TAVR at higher procedural volume centers, had lower in-hospital mortality with shorter LOS and lower costs. These findings highlight the critical role of procedural experience and support directing complex, time-sensitive TAVR cases to high-volume institutions to optimize patient outcomes and healthcare value.